SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/21.03.25 | Delayed Deutsche Boerse AG 11:49:39 05/06/2024 BST | ||
| 0.016 EUR | 0.00% |
|
| Current month | +6.67% | ||
| 1 month | -27.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 05/06/24 | 0.016 | 0.00% |
| 04/06/24 | 0.016 | +6.67% |
| 03/06/24 | 0.015 | 0.00% |
| 31/05/24 | 0.015 | +36.36% |
| 30/05/24 | 0.011 | -8.33% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 11:49 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| WKN | SW3PKH |
| ISIN | DE000SW3PKH7 |
| Date issued | 19/09/2023 |
| Strike | 70 $ |
| Maturity | 21/03/2025 (290 Days) |
| Parity | 10 : 1 |
| Emission price | 0.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.31 € |
|---|---|
| Lowest since issue | 0.009 € |
| Spread | 0.01 € |
| Spread % | 38.46% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.75
USD
Average target price
53.19
USD
Spread / Average Target
+27.41%
- Stock Market
- Warrants
- Warrant